@entity8189 overexpression and resistance to radiotherapy in XXXX .

@entity1 @entity5 @entity8189 @entity189 @entity3 @entity213
Radiotherapy (RT) and surgery are the cornerstones in treating @entity213 ( @entity213 ). RT is effective in the initial treatment of early to intermediate stage @entity213 but less effective for locally advanced disease, some cases of which are best managed using the combination of surgery and RT. Although various clinical/pathologic parameters have been used to classify @entity1 according to their likelihood of responding to RT, they have generally low predictive value. We have shown previously that @entity8189 is associated with a poor clinical outcome in @entity213 @entity1 . In this study, we investigate the potential role of @entity8189 in assessing RT response in @entity1 with @entity213 . Tumor specimens obtained from 80 @entity1 participated in a prospective Phase III clinical trial addressing the dose and fractionation regimen of postoperative RT were analyzed for @entity8189 expression by immunohistochemistry. @entity1 were classified according to currently accepted clinical/pathologic parameters into three risk groups, i.e., low, intermediate, and high risk, and received surgery alone, surgery plus intermediate-dose RT, and surgery plus high-dose RT, respectively. The median follow-up duration was 4.9 years. @entity8189 overexpression was noted in 38 of the 80 (47%) @entity213 . Interestingly, 11 of the 38 @entity1 (29%) with @entity8189 -overexpressing @entity5 experienced local or nodal recurrence compared with only 3 of 42 @entity1 (7%) having @entity189 with no or weak @entity8189 expression (P = 0.01). When locoregional control was used as the end point for the high-risk group, @entity1 whose @entity5 showed @entity8189 overexpression had a statistically significant higher @entity5 recurrence and @entity3 compared with @entity1 whose @entity5 showed no @entity8189 overexpression (P = 0.01). Our results indicate that @entity5 overexpressing @entity8189 may be resistant to RT, and @entity8189 may be an indicator of the risk of locoregional recurrence and @entity3 in @entity1 having @entity213 receiving RT.
